Ng Carey 4

4 · Immix Biopharma, Inc. · Filed May 29, 2026

AI-generated summary of this filing

Updated May 29, 2026

Immix Biopharma (IMMX) Director Ng Carey Receives Award

What Happened

Ng Carey, a director of Immix Biopharma (IMMX), received equity awards reported on Form 4 for transactions dated 2026-05-22.
The filing shows two grants: 6,250 restricted stock units (RSUs) granted at $0.00 and a 12,500-share derivative award (a stock option) also reported at $0.00. The grants have no cash purchase price at grant; the filing does not disclose any option strike price or immediate cash value.

Key Details

Transaction date: 2026-05-22. Form 4 filed: 2026-05-29.
Awards: 6,250 RSUs (vest in full on earlier of the one-year anniversary or the issuer’s 2027 annual meeting, subject to continued service); 12,500-share stock option (vests in substantially equal monthly installments over the 12 months after grant, or any remaining portion at the 2027 annual meeting, subject to continued service). (Footnotes F1, F3)
Reported acquisition price: $0.00 for both awards (grant value not stated on Form 4; option strike not disclosed).
Shares owned after the transaction: not specified in the provided filing details.
Reporting relationship: Ng Carey is also Managing Director of Mesa Verde Venture Partners III, LP and disclaims beneficial ownership of securities held by that entity except to the extent of any pecuniary interest. (Footnote F2)
Filing timing: the report was filed seven days after the transaction date (5/22 → 5/29); typical Form 4 deadline is within 2 business days of the transaction, so this gap is notable.

Context

These are grant/award transactions (code A), not open-market purchases or sales — they reflect compensation/equity incentives rather than immediate insider buying or selling.
RSUs and restricted option awards often vest over time and are contingent on continued service; they do not necessarily indicate near-term selling or buying by the insider.
For retail investors, awards to directors are common as compensation/retention tools; they are informative about alignment but not a direct market transaction indicating conviction.

Form 4

Period: 2026-05-22

Director

Transactions

Award
Common Stock
[F1]
2026-05-22+6,250→ 26,250 total
Award
Stock Option (Right to Buy)
[F3]
2026-05-22+12,500→ 12,500 total
Exercise: $8.78Exp: 2036-05-22→ Common Stock (12,500 underlying)

Holdings

Footnotes (3)

[F1]The Reporting Person was granted 6,250 restricted stock units ("RSUs") pursuant to the Issuer's 2021 Equity Incentive Plan, which RSUs will vest in full on the earlier of (i) the one-year anniversary of the date of grant, and (ii) the date that the Issuer's 2027 annual meeting of stockholders (the "2027 Annual Meeting") is held, subject to the Reporting Person's continued service with the Issuer.
[F2]The Reporting Person is the Managing Director of Mesa Verde Venture Partners III, LP ("Mesa Verde") and in such capacity has the right to vote and dispose of the securities held by such entity. The Reporting Person disclaims beneficial ownership of the securities held by Mesa Verde, except to the extent of his pecuniary interest therein.
[F3]The stock option will vest in substantially equal monthly installments over the 12 months following the date of grant (or, in the event the 2027 Annual Meeting occurs prior to the first anniversary of the date of grant, any remaining unvested portion of the stock option will vest on the date of such 2027 Annual Meeting), subject to the Reporting Person's continued service on the Issuer's Board through the applicable vesting date.

Signature

/s/ Ilya Rachman as Attorney-In-Fact for Carey Ng|2026-05-29

1 file